Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 12/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24879201 | 1.00 | PTPN11 (0.33) | PTPN11KRASMAPK3MAPK1 | |
| SCHEMBL27216137 | 0.93 | PTPN11 (0.35) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27454080 | 0.87 | PTPN11 (0.35) | PTPN11MAPK3MAPK1 | |
| SCHEMBL30110926 | 0.87 | PTPN11 (0.35) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27460213 | 0.87 | PTPN11 (0.36) | PTPN11MAPK3MAPK1 | |
| SCHEMBL30110905 | 0.80 | PTPN11 (0.48) | PTPN11 | |
| SCHEMBL24879098 | 0.80 | PTPN11 (0.48) | PTPN11 | |
| SCHEMBL27216058 | 0.79 | PTPN11 (0.37) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24879061 | 0.79 | PTPN11 (0.37) | PTPN11 | |
| SCHEMBL22050027 | 0.78 | CKS1B (0.36) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885KRAS 156/4885MAPK3 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.